Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin vs Silodosin on Pupil Size and Choroidal Thickness in BPH
NCT07743060Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Drugs
- tamsulosinsilodosin
- Conditions
- benign prostatic hyperplasia (BPH)
01
Overview
Phase 4, randomised trial in benign prostatic hyperplasia (BPH) comparing Group 1: Tamsulosin with Group 2: Silodosin (2 arms). Primary endpoints: Mean change in pupil diameter at 3 months and Mean change in choroidal thickness at 3 months. Planned start Aug 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Group 1: Tamsulosin
Tamsulosin 0.4 mg, daily.
Group 2: Silodosin
Silodosin 8 mg, daily.
03
Who it enrols
Men aged 50+ with BPH and moderate symptoms (IPSS 8-19), no prior alpha-blocker use, and no history of intraocular surgery, active ocular disease, diabetes, or hypertension.
04
Endpoints
Primary
Mean change in pupil diameter
Mean change in choroidal thickness
Beyond the preview
Go deeper on NCT07743060.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743060.